Process Development and Scale-Up of RLY-2139: A Selective CDK2 Inhibitor Targeting ER+/HER2– Breast Cancer

发表于 2026-9-8 10:34:58

期刊：Organic Process Research & Development

文献作者：Seema Bag; Allen Qinglin Che; Andre Lescarbeau; Daniel Jones; Vishnu Karnati; Jing He; Alexander Merton Taylor; Charles Heap; Tim Briggs; Jianglin Colin Liang; Jay Larrow; Lingzhu Kong; Jin Zhang; Song Guo; Liyu Wang; Licheng Song; Surendra Singh

出版日期：2026-2-20

DOI号：10.1021/acs.oprd.5c00342

下载链接：https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.5c00342

文献链接：https://doi.org/10.1021/acs.oprd.5c00342

当前文献来源于 American Chemical Society (ACS)。

备注信息：

发表于 2026-9-8 10:34:59

: 当前求助已完成，请重新发起求助。
已完结状态的附件将会在24小时内删除。

[ACS] Process Development and Scale-Up of RLY-2139: A Selective CDK2 Inhibitor Targeting ER+/HER2– Breast Cancer

已采纳

同分类求助

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[ACS] Process Development and Scale-Up of RLY-2139: A Selective CDK2 Inhibitor Targeting ER+/HER2– Breast Cancer 一键复制